Beyondspring’s (BYSI) Buy Rating Reiterated at Maxim Group

Maxim Group reiterated their buy rating on shares of Beyondspring (NASDAQ:BYSI) in a research report sent to investors on Wednesday, February 7th. The brokerage currently has a $52.00 target price on the stock.

“On January 29th, BeyondSpring hosted a KOL call to discuss its lead asset, Plinabulin. Dr. Douglas Blayney, a founding member of the NCCN neutropenia management guideline panel, spoke on the call regarding Plinabulin and the ongoing phase 2/3 trial, Study 105 for the prevention of docetaxel chemotherapy-induced neutropenia (CIN).”,” the firm’s analyst wrote.

Several other research firms have also commented on BYSI. HC Wainwright set a $60.00 target price on Beyondspring and gave the company a buy rating in a report on Thursday, October 26th. Zacks Investment Research raised Beyondspring from a sell rating to a hold rating in a report on Tuesday, January 9th. Finally, Seaport Global Securities assumed coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They issued a buy rating and a $56.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Beyondspring has an average rating of Buy and an average price target of $54.50.

Beyondspring (BYSI) opened at $26.12 on Wednesday. Beyondspring has a twelve month low of $16.55 and a twelve month high of $48.49.

An institutional investor recently bought a new position in Beyondspring stock. Tanaka Capital Management Inc. acquired a new stake in Beyondspring Inc (NASDAQ:BYSI) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring makes up about 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th largest position. Tanaka Capital Management Inc. owned 0.10% of Beyondspring as of its most recent filing with the Securities and Exchange Commission (SEC). 1.22% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/16/maxim-group-reiterates-buy-rating-for-beyondspring-bysi.html.

Beyondspring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply